Literature DB >> 35101279

Muscarinic receptors: from clinic to bench to clinic.

Daniel J Foster1.   

Abstract

Efforts to target muscarinic acetylcholine receptors in the brain have been hampered by dose-limiting side effects. In a tour de force of team science, Brown and colleagues have designed a muscarinic agonist that has been optimized to possess properties that could position it to succeed where other agonists have failed.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  behavioral pharmacology; clinical trials; drug discovery; molecular pharmacology; neuroscience; structural biology

Mesh：

Substances：

Year:  2022        PMID： 35101279      PMCID： PMC9486979          DOI： 10.1016/j.tips.2022.01.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   17.638


  10 in total

1.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Authors:  N C Bodick; W W Offen; A I Levey; N R Cutler; S G Gauthier; A Satlin; H E Shannon; G D Tollefson; K Rasmussen; F P Bymaster; D J Hurley; W Z Potter; S M Paul
Journal:  Arch Neurol       Date:  1997-04

2.  Design and Synthesis of γ- and δ-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity.

Authors:  Jennifer E Davoren; Michelle Garnsey; Betty Pettersen; Michael A Brodney; Jeremy R Edgerton; Jean-Philippe Fortin; Sarah Grimwood; Anthony R Harris; Stephen Jenkinson; Terry Kenakin; John T Lazzaro; Che-Wah Lee; Susan M Lotarski; Lisa Nottebaum; Steven V O'Neil; Michael Popiolek; Simeon Ramsey; Stefanus J Steyn; Catherine A Thorn; Lei Zhang; Damien Webb
Journal:  J Med Chem       Date:  2017-07-26       Impact factor: 7.446

3.  Structures of the M1 and M2 muscarinic acetylcholine receptor/G-protein complexes.

Authors:  Shoji Maeda; Qianhui Qu; Michael J Robertson; Georgios Skiniotis; Brian K Kobilka
Journal:  Science       Date:  2019-05-10       Impact factor: 47.728

4.  From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.

Authors:  Alastair J H Brown; Sophie J Bradley; Fiona H Marshall; Giles A Brown; Kirstie A Bennett; Jason Brown; Julie E Cansfield; David M Cross; Chris de Graaf; Brian D Hudson; Louis Dwomoh; João M Dias; James C Errey; Edward Hurrell; Jan Liptrot; Giulio Mattedi; Colin Molloy; Pradeep J Nathan; Krzysztof Okrasa; Greg Osborne; Jayesh C Patel; Mark Pickworth; Nathan Robertson; Shahram Shahabi; Christoffer Bundgaard; Keith Phillips; Lisa M Broad; Anushka V Goonawardena; Stephen R Morairty; Michael Browning; Francesca Perini; Gerard R Dawson; John F W Deakin; Robert T Smith; Patrick M Sexton; Julie Warneck; Mary Vinson; Tim Tasker; Benjamin G Tehan; Barry Teobald; Arthur Christopoulos; Christopher J Langmead; Ali Jazayeri; Robert M Cooke; Prakash Rucktooa; Miles S Congreve; Malcolm Weir; Andrew B Tobin
Journal:  Cell       Date:  2021-11-24       Impact factor: 41.582

5.  Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.

Authors:  Stephen K Brannan; Sharon Sawchak; Andrew C Miller; Jeffrey A Lieberman; Steven M Paul; Alan Breier
Journal:  N Engl J Med       Date:  2021-02-25       Impact factor: 91.245

6.  Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Authors:  Anantha Shekhar; William Z Potter; Jeffrey Lightfoot; John Lienemann; Sanjay Dubé; Craig Mallinckrodt; Frank P Bymaster; David L McKinzie; Christian C Felder
Journal:  Am J Psychiatry       Date:  2008-07-01       Impact factor: 18.112

7.  M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition.

Authors:  Sean P Moran; Jonathan W Dickerson; Hyekyung P Cho; Zixiu Xiang; James Maksymetz; Daniel H Remke; Xiaohui Lv; Catherine A Doyle; Deepa H Rajan; Colleen M Niswender; Darren W Engers; Craig W Lindsley; Jerri M Rook; P Jeffrey Conn
Journal:  Neuropsychopharmacology       Date:  2018-03-14       Impact factor: 7.853

8.  TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects.

Authors:  Yuu Sako; Emi Kurimoto; Takao Mandai; Atsushi Suzuki; Maiko Tanaka; Motohisa Suzuki; Yuji Shimizu; Masami Yamada; Haruhide Kimura
Journal:  Neuropsychopharmacology       Date:  2018-08-01       Impact factor: 7.853

Review 9.  Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sean P Moran; James Maksymetz; P Jeffrey Conn
Journal:  Trends Pharmacol Sci       Date:  2019-11-08       Impact factor: 14.819

10.  Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.

Authors:  Sophie J Bradley; Colin Molloy; Paulina Valuskova; Louis Dwomoh; Miriam Scarpa; Mario Rossi; Lisa Finlayson; Kjell A Svensson; Eyassu Chernet; Vanessa N Barth; Karolina Gherbi; David A Sykes; Caroline A Wilson; Rajendra Mistry; Patrick M Sexton; Arthur Christopoulos; Adrian J Mogg; Elizabeth M Rosethorne; Shuzo Sakata; R A John Challiss; Lisa M Broad; Andrew B Tobin
Journal:  Nat Chem Biol       Date:  2020-02-20       Impact factor: 15.040
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.